RecruitingPhase 1NCT06366490

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PhotonPharma, Inc.
Intervention
Innocell Autologous Cellular Immunotherapy(biological)
Enrollment
8 enrolled
Eligibility
18 years · FEMALE
Timeline
20262026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06366490 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials